Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@mtheory11bio Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1555606459.png) @mtheory11bio Chris Carper

Chris Carper posts on X about $alec, $bhvn, $crvs, $kymr the most. They currently have XXXXX followers and X posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1555606459/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1555606459/c:line/m:interactions.svg)

- X Week XXXXXX +246%
- X Month XXXXXX -XX%
- X Months XXXXXXX +27%
- X Year XXXXXXX -XX%

### Mentions: X [#](/creator/twitter::1555606459/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1555606459/c:line/m:posts_active.svg)

- X Week X +133%
- X Month XX -XX%
- X Months XX +42%
- X Year XXX -XX%

### Followers: XXXXX [#](/creator/twitter::1555606459/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1555606459/c:line/m:followers.svg)

- X Week XXXXX +0.23%
- X Month XXXXX +4.90%
- X Months XXXXX +11%
- X Year XXXXX +13%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1555606459/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1555606459/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1555606459/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [currencies](/list/currencies)  XXXX%

**Social topic influence**
[$alec](/topic/$alec) 25%, [$bhvn](/topic/$bhvn) 12.5%, [$crvs](/topic/$crvs) 12.5%, [$kymr](/topic/$kymr) 12.5%, [$500m](/topic/$500m) 12.5%, [$35b](/topic/$35b) 12.5%, [number of](/topic/number-of) 12.5%, [$lrmr](/topic/$lrmr) 12.5%, [$tecx](/topic/$tecx) 12.5%, [$azn](/topic/$azn) XXXX%

**Top accounts mentioned or mentioned by**
[@jonnyfunguy](/creator/undefined) [@stocksdd](/creator/undefined) [@mufaso7](/creator/undefined) [@stephanklingel1](/creator/undefined)

**Top assets mentioned**
[Biohaven Pharmaceutical Holding Company Ltd. (BHVN)](/topic/$bhvn) [Kymera Therapeutics, Inc. Common Stock (KYMR)](/topic/$kymr) [AstraZeneca PLC (AZN)](/topic/$azn)
### Top Social Posts [#](/creator/twitter::1555606459/posts)
---
Top posts by engagements in the last XX hours

"$BHVN is interesting because would the FDA say haha j/k in a CRL if troriluzole hit X pre-specified primary and secondary endpoints in the RWE study that the FDA helped design"  
[X Link](https://x.com/mtheory11bio/status/1973743867393699948) [@mtheory11bio](/creator/x/mtheory11bio) 2025-10-02T13:36Z 5247 followers, 17.7K engagements


"$CRVS $KYMR Theres room for multiple winners in the oral AD space but this valuation gap is interesting"  
[X Link](https://x.com/mtheory11bio/status/1968359990663741462) [@mtheory11bio](/creator/x/mtheory11bio) 2025-09-17T17:02Z 5249 followers, 4901 engagements


"1/ $ALEC reduced the number of patients for INFRONT-3 to 90-100 symptomatic patients vs the previous XXX total patients based on a blinded SSRE. They stated that the SSRE demonstrated the variability of disease progression is considerably less than their initial estimates"  
[X Link](https://x.com/mtheory11bio/status/1975602784876830875) [@mtheory11bio](/creator/x/mtheory11bio) 2025-10-07T16:43Z 5248 followers, 2567 engagements


"@Jonny_fun_guy Just in terms of INFRONT-3 success I think $ALEC would get some credit for success by elevating PGRN in other indications thus validating the $XXX upfront they received from GSK. Im not as concerned about commercial prospects for this one indication while its trading at $3"  
[X Link](https://x.com/mtheory11bio/status/1975623622040690812) [@mtheory11bio](/creator/x/mtheory11bio) 2025-10-07T18:05Z 5250 followers, XXX engagements


"$LRMR: our drug was generally well tolerated except when it wasnt"  
[X Link](https://x.com/mtheory11bio/status/1972619203401392373) [@mtheory11bio](/creator/x/mtheory11bio) 2025-09-29T11:07Z 5248 followers, 4892 engagements


"Like the setup for $TECX as expectations are low heading into the HFrEF + $AZN Re-PHIRE readouts. The primary endpoint for Re-PHIRE is change in PVR vs pbo but w/ the inclusion of ipcPH patients (which have normal PVR) secondary endpoints and subgroups should be more important"  
[X Link](https://x.com/mtheory11bio/status/1978474430461366607) [@mtheory11bio](/creator/x/mtheory11bio) 2025-10-15T14:53Z 5247 followers, 3017 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@mtheory11bio Avatar @mtheory11bio Chris Carper

Chris Carper posts on X about $alec, $bhvn, $crvs, $kymr the most. They currently have XXXXX followers and X posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

  • X Week XXXXXX +246%
  • X Month XXXXXX -XX%
  • X Months XXXXXXX +27%
  • X Year XXXXXXX -XX%

Mentions: X #

Mentions Line Chart

  • X Week X +133%
  • X Month XX -XX%
  • X Months XX +42%
  • X Year XXX -XX%

Followers: XXXXX #

Followers Line Chart

  • X Week XXXXX +0.23%
  • X Month XXXXX +4.90%
  • X Months XXXXX +11%
  • X Year XXXXX +13%

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% currencies XXXX%

Social topic influence $alec 25%, $bhvn 12.5%, $crvs 12.5%, $kymr 12.5%, $500m 12.5%, $35b 12.5%, number of 12.5%, $lrmr 12.5%, $tecx 12.5%, $azn XXXX%

Top accounts mentioned or mentioned by @jonnyfunguy @stocksdd @mufaso7 @stephanklingel1

Top assets mentioned Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Kymera Therapeutics, Inc. Common Stock (KYMR) AstraZeneca PLC (AZN)

Top Social Posts #

Top posts by engagements in the last XX hours

"$BHVN is interesting because would the FDA say haha j/k in a CRL if troriluzole hit X pre-specified primary and secondary endpoints in the RWE study that the FDA helped design"
X Link @mtheory11bio 2025-10-02T13:36Z 5247 followers, 17.7K engagements

"$CRVS $KYMR Theres room for multiple winners in the oral AD space but this valuation gap is interesting"
X Link @mtheory11bio 2025-09-17T17:02Z 5249 followers, 4901 engagements

"1/ $ALEC reduced the number of patients for INFRONT-3 to 90-100 symptomatic patients vs the previous XXX total patients based on a blinded SSRE. They stated that the SSRE demonstrated the variability of disease progression is considerably less than their initial estimates"
X Link @mtheory11bio 2025-10-07T16:43Z 5248 followers, 2567 engagements

"@Jonny_fun_guy Just in terms of INFRONT-3 success I think $ALEC would get some credit for success by elevating PGRN in other indications thus validating the $XXX upfront they received from GSK. Im not as concerned about commercial prospects for this one indication while its trading at $3"
X Link @mtheory11bio 2025-10-07T18:05Z 5250 followers, XXX engagements

"$LRMR: our drug was generally well tolerated except when it wasnt"
X Link @mtheory11bio 2025-09-29T11:07Z 5248 followers, 4892 engagements

"Like the setup for $TECX as expectations are low heading into the HFrEF + $AZN Re-PHIRE readouts. The primary endpoint for Re-PHIRE is change in PVR vs pbo but w/ the inclusion of ipcPH patients (which have normal PVR) secondary endpoints and subgroups should be more important"
X Link @mtheory11bio 2025-10-15T14:53Z 5247 followers, 3017 engagements

@mtheory11bio
/creator/twitter::mtheory11bio